Verastem Oncology Reports Third Quarter 2019 Financial Results and Recent Company Progress
Verastem Oncology has reported $9 Million in total revenue, including $4.0 Million in net product revenue from COPIKTRA®; Reaffirms FY2019…
Pharmaceuticals, Biotechnology and Life Sciences
Verastem Oncology has reported $9 Million in total revenue, including $4.0 Million in net product revenue from COPIKTRA®; Reaffirms FY2019…
Seattle Genetics has record Adcetris net sales in U.S. and Canada of $167.6 Million in the third quarter, an increase…
Blueprint Medicines Corporation said in an update on its New Drug Application (NDA) for avapritinib for the treatment of adults with PDGFRA , that the FDA has said it plans to administratively split the proposed indications for avapritinib into two separate NDAs, one for PDGFRA Exon 18 mutant GIST, regardless of prior therapy, and one for fourth-line GIST.
FDA has expanded the duration of use of Allergan’s Lilleta to prevent pregnancy for up to six years, after Supplemental…
Medpace Holdings has posted revenue of $216.2 million in the third quarter of 2019, as it increased 20.6% from revenue…
Progenity has presented data on a study showing the potential for improved efficacy in treating inflammatory bowel disease (IBD) when…
HAYWARD, Calif.–(BUSINESS WIRE)–Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Antoni…
Mirum Pharmaceuticals has appointed Ed Tucker as Chief Medical Officer, the company said Monday.
AstraZeneca announced Monday that Imfinzi (durvalumab) and IMFINZI Plus Tremelimumab Delayed Disease Progression in Phase III POSEIDON Trial for 1st-Line…
5-Center Study of the Device is Intended to Provide Clinical Data in Support of MedRhythms’ FDA Submission.